{"id":"W2589237569","doi":"10.1186/s13045-017-0417-z","title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Medicine; Placebo; Myelofibrosis; Internal medicine; Randomized controlled trial; Population; Adverse effect; Clinical endpoint; Surgery; Pathology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01267266,0.0006019392,0.002422172,0.0004520105,0.000434234,0.001744426,0.001004364,0.001866291,0.002558852],"category_scores_gemma":[0.0076928,0.0003012504,0.00254236,0.0007744055,0.0005524384,0.001120346,0.00047556,0.002329881,0.0004441157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001003553,"about_ca_system_score_gemma":0.001562725,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008832482,"about_ca_topic_score_gemma":0.002706391,"domain_scores_codex":[0.9965562,0.001992705,0.0004356706,0.0001900616,0.0006153745,0.000210054],"domain_scores_gemma":[0.99221,0.00292091,0.002612583,0.0003769631,0.001168411,0.0007111317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5091101,0.003153137,0.01545209,0.01262985,0.01087749,0.0002722639,0.0004170258,0.0009088275,0.005662626,0.001272224,0.03478935,0.405455],"study_design_scores_gemma":[0.7094121,0.06750567,0.08063069,0.006034248,0.01889959,0.001021035,0.0002763875,0.001414422,0.002704237,0.001238608,0.1106693,0.0001937067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.42533,0.5260835,0.004192991,0.01518103,0.003069317,0.003904929,0.0104355,0.000478535,0.0113241],"genre_scores_gemma":[0.7774659,0.1588929,0.008297149,0.02502229,0.003635514,0.005957115,0.01741413,0.0001438973,0.00317121],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01267266,"threshold_uncertainty_score":0.06702024,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03706328763014617,"score_gpt":0.3607162889532588,"score_spread":0.3236530013231126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}